๐
Natalizumab Elan Pharma
natalizumab
Malattia di Crohn
โ Refused
โ
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.
A cosa serve
Treatment of moderately to severely active Crohn's disease for the reduction of signs and symptoms, and the induction and maintenance of sustained response and remission, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or are intolerant to or have medical contraindications to such therapies.
โ ๏ธ Sicurezza del paziente
No
Pagina ufficiale EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/natalizumab-elan-pharma